INNOVIVA, INC. Cash and Cash Equivalents, Period Increase (Decrease)
INNOVIVA, INC. (INVA) reported Cash and Cash Equivalents, Period Increase (Decrease) of $13.89 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-07-26.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-07-26
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $60.09M.
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$46.20M, a 210.54% decline year-over-year.
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$65.08M, a 362.19% decline year-over-year.
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $10.78M.
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$44.68M.
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$41.16M, a 165.99% decline from fiscal 2015.
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $62.38M.
- INNOVIVA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$46.71M, a 195.99% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $60.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $13.89M 10-Q · filed 2018-07-26 | -$51.19M derived: sum of 3 quarters · filed 2018-07-26 | -$40.41M derived: sum of 4 quarters · filed 2018-07-26 |
| 2018-03-31 | -$46.20M 10-Q · filed 2018-05-04 | -$111.28M derived: sum of 2 quarters · filed 2018-05-04 | -$100.50M derived: sum of 3 quarters · filed 2018-05-04 | -$132.67M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-12-31 | -$65.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | -$54.30M derived: sum of 2 quarters · filed 2018-02-23 | -$86.47M derived: sum of 3 quarters · filed 2018-07-26 | -$44.68M 10-K · filed 2018-02-23 |
| 2017-09-30 | $10.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$21.39M derived: sum of 2 quarters · filed 2018-07-26 | $20.40M 10-Q · filed 2017-11-03 | $45.22M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-06-30 | -$32.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $9.62M 10-Q · filed 2018-07-26 | $34.44M derived: sum of 3 quarters · filed 2018-07-26 | $14.69M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | $41.79M 10-Q · filed 2018-05-04 | $66.61M derived: sum of 2 quarters · filed 2018-05-04 | $46.86M derived: sum of 3 quarters · filed 2018-05-04 | $8.03M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $24.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $5.07M derived: sum of 2 quarters · filed 2018-02-23 | -$33.76M derived: sum of 3 quarters · filed 2018-02-23 | -$41.16M 10-K · filed 2018-02-23 |
| 2016-09-30 | -$19.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$58.58M derived: sum of 2 quarters · filed 2017-11-03 | -$65.99M 10-Q · filed 2017-11-03 | $14.45M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | -$38.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$46.23M 10-Q · filed 2017-08-08 | $34.20M derived: sum of 3 quarters · filed 2018-02-23 | -$36.63M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | -$7.40M 10-Q · filed 2017-05-05 | $73.03M derived: sum of 2 quarters · filed 2018-02-23 | $2.20M derived: sum of 3 quarters · filed 2018-02-23 | $10.59M derived: sum of 4 quarters · filed 2018-02-23 |
| 2015-12-31 | $80.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $9.60M derived: sum of 2 quarters · filed 2018-02-23 | $17.99M derived: sum of 3 quarters · filed 2018-02-23 | $62.38M 10-K · filed 2018-02-23 |
| 2015-09-30 | -$70.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$62.44M derived: sum of 2 quarters · filed 2016-11-03 | -$18.05M 10-Q · filed 2016-11-03 | -$40.83M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $8.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $52.78M 10-Q · filed 2016-08-04 | $30.00M derived: sum of 3 quarters · filed 2017-02-28 | -$58.47M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $44.39M 10-Q · filed 2016-05-05 | $21.61M derived: sum of 2 quarters · filed 2017-02-28 | -$66.87M derived: sum of 3 quarters · filed 2017-02-28 | $15.91M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | -$22.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$111.25M derived: sum of 2 quarters · filed 2017-02-28 | -$28.48M derived: sum of 3 quarters · filed 2017-02-28 | -$46.71M 10-K · filed 2017-02-28 |
| 2014-09-30 | -$88.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$5.70M derived: sum of 2 quarters · filed 2015-11-05 | -$23.93M 10-Q · filed 2015-11-05 | -$52.32M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-30 | $82.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $64.54M 10-Q · filed 2015-08-06 | $36.16M derived: sum of 3 quarters · filed 2016-02-24 | $8.81M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-31 | -$18.23M 10-Q · filed 2015-05-08 | -$46.62M derived: sum of 2 quarters · filed 2016-02-24 | -$73.97M derived: sum of 3 quarters · filed 2016-02-24 | |
| 2013-12-31 | -$28.38M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | -$55.73M derived: sum of 2 quarters · filed 2016-02-24 | $48.66M 10-K · filed 2016-02-24 | |
| 2013-09-30 | -$27.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $77.04M 10-Q · filed 2014-11-04 | ||
| 2013-06-30 | $104.39M 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $50.07M 10-K · filed 2015-02-27 | |||
| 2011-06-30 | -$72.67M 10-Q · filed 2011-08-03 | |||
| 2010-06-30 | $22.18M 10-Q · filed 2011-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |